Aurobindo Pharma Limited

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the incorporation of a new wholly owned subsidiary, Avogent Lifesciences Private Limited, in India by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.

Aurobindo Pharma Limited

Aurobindo Pharma Limited's wholly owned subsidiary Lannett Company LLC has launched a generic version of Advair Diskus in the US market, marking the first product from Aurobindo's inhalation pipeline to be commercialized in the US.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the completion of US FDA inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary, with three procedural observations.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has submitted the Exchange a copy Srutinizers report of AGM held on August 27, 2026, and voting results. All resolutions have been approved by the shareholders with requisite majority.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has submitted the Proceedings of 39th Annual General Meeting held on August 27, 2026. The meeting was attended by 86 members through video conferencing or other audio-visual means. The Chairman addressed the shareholders and spoke about the Company's financial performance and future growth plans.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the schedule of an investor/analyst meeting to be held on September 1-2, 2026 in Hong Kong.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about a scheduled investor/analyst meeting on September 1, 2026, in Mumbai, where officials will participate in one-on-one and group meetings.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the completion of a US FDA inspection at Lannett Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA, Inc. The inspection concluded with four procedural observations, and the company will respond to the US FDA within the stipulated timeline.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the completion of a US FDA inspection at Auro Peptides Ltd, a subsidiary/business arm of the Company. The inspection concluded with only one observation, relating to facility and equipment maintenance, and corrective action was initiated during the inspection. The Company reaffirmed its commitment to maintaining robust quality and compliance standards across its manufacturing facilities.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the classification of the US FDA inspection at its Raleigh Plant, North Carolina, as Voluntary Action Indicated (VAI). The inspection was conducted from March 24, 2025, to April 10, 2025, and resulted in 11 observations. The facility has now been closed, and pending applications for multiple inhalers and other dosage forms can progress through the USFDA's review process.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about its schedule of investor/analyst meetings, including a one-on-one and group meeting with Motilal Oswal on August 19, 2026.

Aurobindo Pharma Limited

Aurobindo Pharma Limited's wholly owned subsidiary, Eugia Pharma Specialities Ltd., received a Warning Letter from the US FDA for its Unit I formulation manufacturing facility, which has received an Official Action Indicated (OAI) status. The company assures that there is no impact on existing supplies to the US markets and is committed to enhancing compliance.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has released the transcript of its Q1FY27 earnings call, highlighting a 16% year-on-year increase in consolidated revenues to Rs. 9,150 crores, driven by strong performance across its business areas, including European and US markets. The company also completed the Lannett acquisition, which adds scale, strengthens its US platform, and enhances its competitive position.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has incorporated a new wholly owned subsidiary company named Auropharm Overseas Limited in India. The subsidiary was incorporated on August 13, 2026, with an initial subscription to the share capital of Rs. 10,00,000 divided into 1,00,000 equity shares of Rs. 10 each. The object of incorporation is to undertake manufacturing and marketing operations in India and foreign countries.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has announced a special window for re-lodgement of transfer requests of physical shares, and TAAL Tech Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at ₹7,294.23 crore and net profit before tax at ₹343.97 crore.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has published newspaper advertisements for its first quarter ended June 30, 2026, financial results in Business Standard and Nava Telangana on August 7, 2026.

Aurobindo Pharma Limited

Aurobindo Pharma Limited officials will participate in an investor/analyst meeting in Singapore and Hong Kong from August 11 to 13, 2026. The meeting schedule is subject to change due to exigence. No unpublished price-sensitive information will be discussed during the interactions.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has proposed a merger of its two wholly-owned step-down subsidiaries, Eugia Steriles Private Limited and Eugia SEZ Private Limited, with its wholly-owned subsidiary, Eugia Pharma Specialities Limited. The merger aims to simplify the group structure, eliminate corporate and administrative functions, and achieve cost reduction and synergy benefits.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has announced its unaudited financial results for the first quarter ended June 30, 2026, with revenue from operations increasing by 16.3% YoY to INR 9,150 Cr, and net profit for the period standing at INR 1,032 Cr.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has released its Q1FY27 earnings presentation, highlighting a 16.3% year-over-year revenue growth, driven by strong performance across all business areas, with US base business continuing to grow driven by volume gains and new launches. Operating EBITDA stood at ₹1,924 Cr with a margin of 21.0%. The company has received final approval for 10 products and launched 10 products in the US market.